Giant cell arteritis

1. High-Yield Summary

Giant cell arteritis (GCA), historically termed temporal arteritis or Horton disease, is a systemic granulomatous panarteritis that exclusively targets medium and large arteries in individuals aged 50 years and older:

• Definition & Vascular Predilection: Giant cell arteritis is the most common primary systemic vasculitis in older adults. It preferentially involves the cranial branches of the external and internal carotid arteries (notably the superficial temporal, ophthalmic, posterior ciliary, and vertebral arteries) as well as the aorta and its major branches (subclavian, axillary, and thoracic aorta).
• Ocular Emergency & Immediate Empiric Glucocorticoids: Ischemic optic neuropathy, most commonly arteritic anterior ischemic optic neuropathy (A-AION) secondary to posterior ciliary artery occlusion, produces catastrophic, painless, irreversible blindness in 15% to 20% of untreated patients, with bilateral visual loss occurring within days to weeks if left unmanaged. Systemic corticosteroid therapy (oral prednisone 40 to 60 mg daily for uncomplicated cranial disease; intravenous methylprednisolone pulse therapy 500 to 1,000 mg daily for 3 consecutive days for acute visual loss or amaurosis fugax) must be initiated immediately upon clinical suspicion and must never be delayed for diagnostic imaging or biopsy.
• Diagnostic Gold Standard & Specimen Thresholds: Unilateral temporal artery biopsy (TAB) remains the histological gold standard. Surgical specimens must achieve an in situ resection length of at least 1.5 to 2.0 cm (fixed length in formalin 1.5 cm or greater) to prevent false-negative results arising from segmental skip lesions. Histopathologic hallmarks (transmural mononuclear inflammatory infiltrates, internal elastic lamina fragmentation, and multinucleated giant cells) persist reliably for 2 to 4 weeks following corticosteroid initiation.
• Surgical Anatomy & Neurovascular Danger Zone: The superficial temporal artery (STA) ascends within the temporoparietal fascia (superficial temporal fascia). The surgical danger zone is dictated by the frontal (temporal) branch of the facial nerve (cranial nerve VII), which crosses the superficial aspect of the zygomatic arch 1.5 to 2.0 cm anterior to the tragus along Pitanguy’s line within the sub-temporoparietal plane. Dissection must remain strictly superficial or proceed via the parietal branch to prevent irreversible frontalis muscle denervation and permanent brow ptosis.
• Targeted Biologics & Steroid-Sparing Innovations: Contemporary management integrates early steroid-sparing targeted agents to counter the severe morbidity of prolonged glucocorticoid therapy (affecting over 80% of patients). Landmark Level I randomized trials have validated the interleukin-6 (IL-6) receptor antagonist tocilizumab (GiACTA trial) and the selective oral Janus kinase 1 (JAK-1) inhibitor upadacitinib (SELECT-GCA trial) for achieving sustained clinical remission and significantly reducing cumulative steroid exposure.

2. Anatomy

Cranial Arterial Architecture & The Superficial Temporal Artery

The superficial temporal artery (STA) represents the smaller of the two terminal branches of the external carotid artery, arising within the deep parenchyma of the parotid gland posterior to the neck of the mandible. From its parotid origin, the artery ascends vertically across the posterior root of the zygomatic process of the temporal bone, situated immediately anterior to the tragus and the external auditory canal. At this preauricular level, the artery is accompanied by the superficial temporal vein (coursing immediately posterior or superficial to the artery) and the auriculotemporal nerve.

As the STA crosses the zygomatic arch, it transitions into the temporal region, embedded securely within the temporoparietal fascia (also designated the superficial temporal fascia, continuous inferiorly with the SMAS and superiorly with the galea aponeurotica). Approximately 2.0 to 4.0 cm superior to the superior margin of the zygomatic arch, the artery divides into its two primary terminal divisions:

• Frontal (Anterior) Branch: Courses tortuously anterosuperiorly toward the frontal eminence of the forehead. It supplies the frontalis muscle, orbicularis oculi, galea aponeurotica, and overlying integument, forming rich anastomoses with the contralateral frontal branch and the supraorbital and supratrochlear branches of the ophthalmic artery (internal carotid circulation).
• Parietal (Posterior) Branch: Courses posterosuperiorly across the temporal and parietal scalp, resting on the superficial temporal fascia overlying the temporalis muscle. It anastomoses with the posterior auricular artery, occipital artery, and contralateral parietal branch.

Ocular and Cerebral Arterial Tributaries

The catastrophic ischemic manifestations of giant cell arteritis result from involvement of branches of the internal carotid and vertebral arterial trees. The ophthalmic artery gives off the medial and lateral short posterior ciliary arteries (typically 2 to 4 primary trunks dividing into 10 to 20 branches), which pierce the sclera around the optic nerve entrance to supply the circle of Zinn-Haller, the choroid, and the laminar and prelaminar regions of the optic nerve head. Vasculitic occlusion of these end-arteries results in arteritic anterior ischemic optic neuropathy (A-AION). Occlusion of the central retinal artery produces extensive inner retinal ischemia (central retinal artery occlusion, CRAO). Occlusion of the posterior circulation (vertebral arteries, basilar trunk) can produce brainstem, cerebellar, or occipital infarction.

Cranial Neurovascular Danger Zone: The Frontal Branch of Cranial Nerve VII

The principal surgical hazard during temporal artery biopsy is iatrogenic transection or traction injury to the temporal (frontal) branch of the facial nerve (cranial nerve VII). The temporal branch exits the anterosuperior border of the parotid gland and ascends diagonally across the middle third of the zygomatic arch, located approximately 1.5 to 2.0 cm anterior to the anterior margin of the external auditory meatus.

The surgical danger zone is clinically mapped along Pitanguy’s line, drawn from a point 0.5 cm inferior to the tragus to a point 1.5 cm superior and lateral to the lateral tail of the eyebrow. At the zygomatic arch, the nerve transitions from a deep sub-fascial location to traverse within the loose subgaleal areolar tissue immediately deep to the temporoparietal fascia. As it ascends toward the frontalis, corrugator supercilii, and superior orbicularis oculi muscles, the nerve innervates these dynamic forehead elevators from their deep muscular surfaces. Plunging surgical incisions, deep subgaleal dissection, or aggressive traction over the zygomatic arch causes unilateral forehead paralysis, complete loss of voluntary eyebrow elevation, and debilitating cosmetic brow ptosis.

Secondary Neural Structures at Risk

Two additional sensory nerve distributions are vulnerable during preauricular and temporal exposures:

• Auriculotemporal Nerve (V3): Emerges from the upper parotid pole directly posterior to the main trunk of the superficial temporal artery anterior to the tragus. Transection or entrapment causes persistent preauricular numbness, painful amputation neuroma, or localized gustatory hyperesthesia.
• Supraorbital and Supratrochlear Nerves (V1): Emerge from the superior orbital margin via the supraorbital notch/foramen and frontal notch. When harvesting the distal frontal branch on the forehead, dissection carried too far medially risks injuring these sensory branches, resulting in cutaneous anesthesia of the central forehead and anterior vertex.

Large-Vessel Distribution: Thoracic Aorta & Upper Extremity Branches

In addition to cranial vasculitis, giant cell arteritis involves the aorta and its major elastic branches in 30% to 50% of patients (large-vessel GCA). The thoracic aorta (ascending aorta, aortic root, and aortic arch) is heavily enriched with elastic fibers and vasa vasorum, rendering it highly susceptible to transmural granulomatous inflammation. Involvement of the subclavian, axillary, and proximal brachial arteries produces long, smooth, tapered, bilateral segmental stenoses that cause upper extremity claudication, cold intolerance, pulse deficits, and vascular steal syndromes.

Surgical Planes and Exposure Corridors for Temporal Artery Biopsy

Safe execution of a temporal artery biopsy requires precise mastery of the layered fascial anatomy of the temporal fossa, proceeding from superficial to deep:

• Skin & Subcutaneous Adipose Tissue: Contains hair follicles and dense fibrous septa connecting dermis to superficial fascia.
• Temporoparietal Fascia (TPF / Superficial Temporal Fascia): The direct anatomic continuation of the galea aponeurotica and SMAS. The superficial temporal artery and vein course directly within this vascular layer. The surgical corridor must enter this layer cleanly.
• Subaponeurotic (Subgaleal) Loose Areolar Tissue: A thin glide plane containing the frontal branch of the facial nerve as it crosses the zygoma. This plane must remain pristine and unviolated during vessel harvest.
• Deep Temporalis Fascia: Dense, glistening white investing aponeurosis covering the temporalis muscle. It splits superior to the zygomatic arch into deep and superficial layers enclosing the intermediate temporal fat pad.
• Temporalis Muscle & Pericranium: Deep muscular and skeletal floor of the temporal fossa.

3. Pathogenesis

Giant cell arteritis is an antigen-driven, immune-mediated granulomatous panarteritis that predominantly affects medium and large elastic arteries. The disease represents a failure of vascular immune privilege, initiated in the adventitia and culminating in occlusive luminal remodeling through a coordinated cellular and molecular cascade:

• Loss of Adventitial Immune Privilege & Dendritic Cell Activation: Normal arterial walls maintain vascular immune tolerance through localized immunosuppressive checkpoints. In GCA, adventitial resident dendritic cells are activated via Toll-like receptors (primarily TLR-4 and TLR-2) by endogenous or exogenous danger-associated molecular patterns (DAMPs). Activated dendritic cells downregulate immunosuppressive programmed death-ligand 1 (PD-L1) and release chemokines (CCL19, CCL21) that recruit circulating mononuclear leukocytes through the adventitial vasa vasorum.
• The Interleukin-17 (Th17) Pro-Inflammatory Pathway: Recruited CD4+ T helper cells stimulated by interleukin-6 (IL-6), IL-23, and IL-1beta differentiate into Th17 effector cells, secreting IL-17, IL-21, and IL-22. This cytokine network drives intense systemic acute-phase reactant synthesis (elevating ESR, CRP, and serum amyloid A), pyrexia, weight loss, and polymyalgic manifestations. The Th17 pathway demonstrates marked sensitivity to glucocorticoids and IL-6 receptor blockade.
• The Interferon-Gamma (Th1) Chronic Granulomatous Pathway: Under stimulation by IL-12 and IL-18, CD4+ T cells polarize into Th1 cells that synthesize interferon-gamma (IFN-gamma). IFN-gamma orchestrates chronic transmural vascular inflammation, directs macrophage recruitment, and resists moderate-dose corticosteroid suppression, driving vascular remodeling, disease chronicity, and late ischemic relapses.
• Macrophage Differentiation, Giant Cell Formation & Elastolysis: Under sustained IFN-gamma stimulation, adventitial monocytes differentiate into destructive M1-like macrophages that migrate inward through the media toward the internal elastic lamina. Macrophages fuse to form foreign-body or Langhans-type multinucleated giant cells. These effector cells release reactive oxygen species, nitric oxide, and matrix metalloproteinases (specifically MMP-2 and MMP-9) that cleave and digest the internal elastic lamina (elastolysis), destroying the structural architecture of the arterial wall.
• Myofibroblastic Intimal Hyperplasia & Luminal Occlusion: In response to vessel injury, macrophages and vascular smooth muscle cells produce powerful growth factors, including Platelet-Derived Growth Factor (PDGF) and Vascular Endothelial Growth Factor (VEGF). PDGF induces medial vascular smooth muscle cells to dedifferentiate, migrate into the subendothelial intimal space, and proliferate as secretory myofibroblasts. This produces concentric, circumferential intimal hyperplasia that progressively obliterates the vascular lumen, causing acute end-organ ischemia. Simultaneously, VEGF stimulates fragile neocapillary angiogenesis within the media, predisposing to micro-thrombosis.

4. Natural History

Epidemiological Profile

Giant cell arteritis is strictly a disease of aging, with disease onset before age 50 being extraordinarily rare (<0.1% of validated cohorts). Incidence increases exponentially with advancing age, peaking in the eighth decade (ages 70 to 79 years) with a mean patient age at diagnosis of 72 to 74 years. Females are disproportionately affected, exhibiting a 2.5:1 to 3:1 female-to-male predilection.

A striking geographic and ancestral gradient characterizes the disease: populations of northern European and Scandinavian ancestry demonstrate the highest worldwide annual incidence (15 to 30 cases per 100,000 individuals aged 50 years and older in Norway, Sweden, Iceland, and Minnesota’s Olmsted County). In contrast, incidence rates among southern European, Mediterranean, Hispanic, African, and Asian populations are substantially lower (1 to 5 cases per 100,000).

Disease Phenotypes and Associated Conditions

Giant cell arteritis presents across two broad, frequently overlapping phenotypic expressions:

• Cranial GCA: Characterized by localized temporal headache, scalp tenderness, jaw claudication, and acute ischemic neuro-ophthalmic complications.
• Large-Vessel GCA (LV-GCA): Characterized by vasculitis of the thoracic aorta, subclavian, axillary, and femoral trunks. Presenting features often include prolonged fever of unknown origin, profound weight loss, refractory anemia, limb claudication, and absence of overt cranial symptoms.
• Polymyalgia Rheumatica (PMR) Overlap: PMR and GCA represent linked clinical entities along a shared pathophysiologic continuum. Approximately 40% to 50% of patients with GCA manifest symptoms of PMR at presentation, whereas 10% to 20% of patients diagnosed initially with isolated PMR subsequently develop clinical or histological GCA.

Natural History of Untreated Disease

If untreated or diagnosed with delay, the natural history of giant cell arteritis is marked by devastating ischemic events. Irreversible vision loss develops in 15% to 20% of patients, predominantly due to A-AION. Involvement of the contralateral eye occurs in up to 50% of untreated individuals within 1 to 2 weeks of the sentinel event. Cerebrovascular stroke, most commonly within the vertebrobasilar territory, occurs in 3% to 4% of active cases.

In patients surviving the acute phase, persistent transmural inflammation of the thoracic aorta causes progressive media degeneration and elastolysis. Patients with GCA carry a 17-fold increased relative risk of thoracic aortic aneurysm compared to age-matched controls, typically presenting as a silent, late manifestation 3 to 7 years following the initial diagnosis, carrying severe risk of sudden aortic dissection or rupture.

5. Clinical Presentation

History

The clinical presentation of giant cell arteritis demands a high index of suspicion, combining localized cranial complaints, ischemic symptoms, and systemic inflammatory signs:

• Headache: The most frequent presenting symptom (70% to 80% of patients). Characteristically of new onset, severe, and localized to the temporal or occipital scalp, though it may be diffuse. Patients describe it as sharp, boring, throbbing, or lancinating, frequently worse at night and recalcitrant to standard analgesics.
• Scalp Tenderness: Reported by 50% to 60% of patients. Manifests as exquisite cutaneous allodynia elicited by routine activities such as hair brushing, wearing eyeglasses, wearing a hat, or resting the head against a pillow.
• Jaw Claudication: Present in 35% to 50% of patients. Defined as fatigue, tightness, or ischemic cramping pain in the masseter and temporalis muscles provoked during mastication of tough food (such as steak, bagels, or gum) that resolves within minutes of jaw rest. Jaw claudication is the single most specific clinical symptom of GCA (specificity > 90%), reflecting ischemia of the maxillary and facial arterial territories. Tongue claudication, lingual infarction, and deglutition pain may also occur.
• Visual Disturbance (Ocular Emergency): Manifests in 20% to 30% of patients as transient monocular visual obscurations (amaurosis fugax), binocular diplopia (due to ischemia of cranial nerves III, IV, or VI), visual field deficits, or sudden, profound, painless monocular blindness. Transient visual symptoms are harbingers of imminent, permanent optic nerve infarction.
• Polymyalgic Manifestations: Symmetrical pain, severe aching, and prolonged morning stiffness (> 45 to 60 minutes) localized to the shoulder girdles, pelvic girdles, and cervical spine. Patients experience functional disability rising from chairs, turning in bed, or elevating their arms to dress.
• Systemic & Large-Vessel Features: Low-grade fever, unexplained weight loss, night sweats, profound anorexia, upper extremity claudication during overhead tasks, Raynaud phenomenon, and thoracic/interscapular back pain.

Physical Exam

Physical examination must systematically evaluate the cranial arteries, visual apparatus, and peripheral vascular tree:

• Superficial Temporal Artery Palpation: Gentle bilateral digital palpation along the course of the main preauricular trunk, frontal branch, and parietal branch -> Thickened, nodular, tender, indurated (“cord-like”), or pulseless temporal artery [Sensitivity 55-65%, Specificity 85-90%].
• Scalp Allodynia Provocation: Gentle manual hair brushing or light cutaneous pinprick over the temporal and occipital regions -> Elicitation of sharp cutaneous hyperesthesia and localized grimacing [Sensitivity 45-55%, Specificity 75-80%].
• Masticatory Claudication Test: Continuous chewing of firm gum for 2 minutes -> Onset of severe ischemic cramping and fatigue in masseter muscles resolving promptly upon cessation [Sensitivity 35-40%, Specificity 90-95%].
• Swinging-Flashlight Pupillary Test (RAPD): Alternating illumination between normal and affected eyes in dim lighting -> Relative Afferent Pupillary Defect (Marcus Gunn pupil), where the affected pupil paradoxically dilates when light swings to it [Sensitivity 70-80% in acute visual loss, Specificity 95-98%].
• Dilated Fundoscopic Examination: Direct and indirect ophthalmoscopy of the optic disc -> Pallid, chalky-white optic disc edema with splinter peripapillary hemorrhages and attenuated arterioles (pathognomonic of A-AION) or diffuse retinal pallor with a cherry-red foveal spot (CRAO) [Sensitivity 75-85% in acute visual loss, Specificity > 95%].
• Bilateral Upper Extremity Vascular Exam: Bilateral simultaneous blood pressure measurement, palpation of carotid, subclavian, brachial, and radial pulses, and auscultation for bruits -> Asymmetry in systolic blood pressure (> 15 to 20 mmHg discrepancy between arms), diminished peripheral pulses, or vascular bruits over the subclavian, axillary, or carotid arteries [Sensitivity 25-35% in cranial GCA, 70-80% in large-vessel GCA, Specificity 90-95%].

6. Imaging and Diagnostic Studies

The diagnostic evaluation of suspected giant cell arteritis follows an algorithmic hierarchy integrating serological biomarkers, noninvasive vascular imaging, and surgical histopathology:

Laboratory Biomarkers

• Erythrocyte Sedimentation Rate (ESR): Markedly elevated by Westergren method, classically exceeding 50 mm/hr and frequently greater than 80 to 100 mm/hr. However, a normal ESR (< 30 mm/hr) is documented in 1% to 4% of biopsy-proven cases and must never be used in isolation to dismiss the diagnosis.
• C-Reactive Protein (CRP): More sensitive than ESR (sensitivity 95% to 98%). Elevated CRP (> 10 mg/L) correlates closely with disease activity, rises earlier during acute flares, and normalizes more rapidly upon treatment response. A discordant profile of elevated CRP with normal ESR occurs in approximately 5% to 10% of patients.
• Complete Blood Count (CBC): Demonstrates normocytic normochromic anemia of chronic disease (hemoglobin 90 to 110 g/L) and reactive thrombocytosis (platelets > 400,000/uL), reflecting interleukin-6-driven hepatic thrombopoietin synthesis. Reactive thrombocytosis correlates with increased risk of permanent cranial ischemic complications.
• Hepatic Profile & Serum Amyloid A: Serum alkaline phosphatase is elevated in 25% to 35% of patients without intrinsic liver disease. Serum amyloid A (SAA) is highly elevated and serves as a sensitive research biomarker.

Temporal Artery Biopsy (Histological Gold Standard)

Unilateral temporal artery biopsy remains the definitive reference standard. To minimize sampling error from “skip lesions” (discontinuous segmental inflammation separated by normal vascular architecture), an in situ arterial segment of at least 1.5 to 2.0 cm must be harvested, which yields a fixed post-formalin specimen length of 1.5 cm or greater. Step-sectioning of the entire specimen block is mandatory.

Histopathologic diagnostic criteria include:

• Transmural Inflammatory Infiltrate: Dense infiltration of mononuclear cells (lymphocytes, histiocytes, macrophages) traversing the adventitia, media, and intima.
• Internal Elastic Lamina Fragmentation (Elastolysis): Severe disruption, focal duplication, or complete enzymatic digestion of the internal elastic lamina, best demonstrated on elastin stains (Verhoeff-Van Gieson).
• Intimal Hyperplasia & Luminal Narrowing: Prominent concentric myofibroblastic expansion of the intima.
• Multinucleated Giant Cells: Langhans-type or foreign-body giant cells clustered along the fragmented internal elastic lamina; present in 50% to 75% of positive specimens. Notably, the presence of giant cells is not mandatory for diagnosis if transmural mononuclear panarteritis and elastolysis are definitively present.

Advanced Vascular Imaging

• Color Doppler Ultrasound (CDUS): Endorsed by EULAR 2023/2024 guidelines as the primary first-line imaging modality for suspected cranial and large-vessel GCA when high-level sonographic expertise is available. Examination must include bilateral common superficial temporal arteries, frontal branches, parietal branches, and axillary arteries. Diagnostic sensitivity ranges from 75% to 85% with a specificity of 94% to 96% against clinical diagnosis.
• Ultrasound Halo Sign: Represents circumferential, hypoechoic, homogenous vessel wall edema visible in both longitudinal and transverse planes throughout the cardiac cycle. Validated diagnostic intima-media thickness cutoffs are 0.34 mm or greater for the temporal artery frontal branch and 1.0 mm or greater for the axillary artery.
• Ultrasound Compression Sign: Confirms true vasculitic wall edema by demonstrating persistence of the hypoechoic halo when the transducer applies sufficient mechanical pressure to fully collapse the arterial lumen, distinguishing vasculitis from acoustic artifact.
• High-Resolution Contrast-Enhanced 3T Vessel-Wall MRI: T1-weighted fat-suppressed post-contrast sequences and black-blood imaging demonstrate circumferential vessel wall thickening, mural edema (T2/STIR hyperintensity), and intense contrast enhancement of the temporal, occipital, and facial arteries. Sensitivity 80% to 90%, Specificity 85% to 92%.
• 18F-Fluorodeoxyglucose (FDG) PET-CT: The modality of choice for confirming large-vessel GCA (LV-GCA) and evaluating occult aortitis. Demonstrates smooth, continuous, circumferential FDG uptake in the thoracic aorta, subclavian, axillary, and iliofemoral arteries exceeding liver uptake (visual score >= 2). Sensitivity 85% to 90% for large-vessel inflammation; ineffective for cranial temporal arteries due to adjacent cerebral cortical avidity.
• CT Angiography (CTA): Evaluates thoracic and abdominal aortic luminal caliber, wall thickening (> 2 to 3 mm), vascular stenosis, occlusion, and aneurysm formation. Serves as the primary structural surveillance tool for late aortic complications.

7. Classification

Classification criteria for giant cell arteritis have evolved significantly over the past three decades. The historical 1990 American College of Rheumatology (ACR) criteria focused entirely on cranial manifestations and histology. In 2022, the American College of Rheumatology and EULAR published modern, validated classification criteria integrating vascular ultrasound, advanced cross-sectional imaging, and large-vessel phenotypes:

The 2022 ACR/EULAR criteria represent a major paradigm shift by assigning equal high weighting (+5 points) to either a positive temporal artery biopsy or a positive ultrasound demonstrating the halo sign in the temporal arteries. Furthermore, the inclusion of axillary artery involvement and aortic PET avidity formally establishes large-vessel GCA within the classification standard.

8. Treatment

Medical / Nonoperative

Medical pharmacotherapy represents the primary therapeutic modality. Management must be initiated emergently upon clinical suspicion to arrest ongoing vascular ischemia:

• Uncomplicated GCA Induction (Oral Prednisone): In patients without visual loss, amaurosis fugax, or neurologic deficits, initiate oral prednisone at 40 to 60 mg daily (or 1 mg/kg/day, capped at 60 mg). Single morning dosing is preferred to minimize hypothalamic-pituitary-adrenal axis suppression. Maintain full induction dose for 2 to 4 weeks until all clinical symptoms remit and inflammatory markers (ESR, CRP) normalize.
• Complicated GCA Induction (Intravenous Methylprednisolone Pulse): In patients presenting with acute visual impairment, amaurosis fugax, diplopia, or evolving stroke, administer high-dose intravenous methylprednisolone pulse therapy at 500 to 1,000 mg IV daily for 3 consecutive days. Pulse therapy delivers rapid genomic and non-genomic suppression of vascular inflammation to preserve remaining vision in the affected eye and protect the contralateral eye, followed by oral prednisone 60 mg daily.
• Systematic Glucocorticoid Tapering Strategy: Following initial clinical and biochemical normalization (at 2 to 4 weeks), taper prednisone systematically: reduce by 10 mg every 2 weeks down to 20 mg daily; then reduce by 2.5 mg every 2 to 4 weeks down to 10 mg daily; then reduce by 1 mg every 4 weeks until complete discontinuation. Total duration of glucocorticoid monotherapy typically spans 12 to 24 months.
• Targeted Biologic Therapy (IL-6 Receptor Antagonist Tocilizumab): Subcutaneous injection of 162 mg weekly (or every other week) combined with a 26-week corticosteroid taper. Supported by the landmark phase 3 GiACTA trial (Stone et al. 2017 NEJM), which demonstrated sustained glucocorticoid-free remission in 56% of patients at 52 weeks compared to 14% with placebo plus a 26-week taper. The 2021 ACR/Vasculitis Foundation guidelines conditionally recommend adding tocilizumab at diagnosis for newly diagnosed GCA and strongly recommend it for relapsing or refractory disease.
• Targeted Small Molecule Therapy (Selective JAK-1 Inhibitor Upadacitinib): Oral 15 mg once daily combined with a 26-week corticosteroid taper. Validated in the phase 3 SELECT-GCA trial (Blockmans et al. 2025 NEJM), demonstrating sustained remission at week 52 in 46% of patients compared to 29% receiving placebo plus a 52-week corticosteroid taper, establishing a potent oral targeted option for steroid-sparing therapy.
• Conventional Synthetic Immunosuppression (Methotrexate): Administered orally or subcutaneously at 15 to 25 mg weekly accompanied by daily folic acid (1 mg). Provides modest steroid-sparing benefit; recommended as an alternative when IL-6 or JAK inhibitors are contraindicated (e.g., active diverticular disease, cytopenias).
• Bone Mineral & Skeletal Prophylaxis: Mandatory baseline DEXA scan, calcium (1,000 to 1,200 mg daily), vitamin D (800 to 1,000 IU daily), and early initiation of bisphosphonates (oral alendronate 70 mg weekly or intravenous zoledronic acid 5 mg annually) to prevent rapid glucocorticoid-induced trabecular bone loss and vertebral compression fractures.
• Gastrointestinal & Infection Prophylaxis: Proton pump inhibitor (pantoprazole 40 mg daily) during high-dose steroid therapy. Trimethoprim-sulfamethoxazole (single-strength daily or double-strength 3 times weekly) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis during prolonged high-dose prednisone (>30 mg for >4 weeks) combined with immunosuppressive biologics.
• Antiplatelet Therapy: Low-dose aspirin (81 to 100 mg daily) should be considered in patients with cranial ischemic symptoms in the absence of contraindications to reduce the risk of cerebrovascular and ocular thrombosis.

Operative Technique: Temporal Artery Biopsy

Surgical execution of a temporal artery biopsy requires rigorous adherence to standardized steps to maximize diagnostic tissue quality and prevent cranial nerve injury:

• Preoperative Doppler Mapping: Identify and trace the superficial temporal artery and its frontal and parietal branches using an 8-MHz continuous-wave Doppler probe or manual palpation. Mark the vessel arborization with a sterile marking pen. The parietal branch is an excellent alternative: it provides equivalent diagnostic yield while traversing well posterior to the facial nerve danger zone.
• Anesthesia & Incision Placement: Infiltrate local anesthetic (1% or 2% lidocaine with 1:100,000 epinephrine) intradermally and into the immediate superficial subcutaneous plane. Avoid direct peri-arterial infiltration to prevent mechanical or pharmacological vasospasm. Make a 3.0 to 4.0 cm curvilinear incision along the marked vessel within the temporal hairline or parallel to relaxed skin creases.
• Dissection Corridor & Fascial Exposure: Perform meticulous blunt spreading in the direction of the vessel fibers using fine tenotomy or Steven’s scissors. Incise the subcutaneous adipose tissue to expose the glistening temporoparietal fascia. Dissect directly within this fascia to isolate the pulsating artery. Dissect the companion vein away cleanly.
• Facial Nerve Danger Zone Avoidance: Dissection must remain strictly superficial to the deep temporalis fascia. Never penetrate the subgaleal plane across the zygomatic arch along Pitanguy’s line, avoiding traction or transection of the frontal branch of cranial nerve VII.
• Vessel Mobilization & Harvest Parameters: Handle the artery exclusively by its adventitial sheath using fine micro-forceps (jeweler’s forceps). Never crush the muscular media with hemostatic clamps. Secure all side branches with fine 4-0 or 5-0 absorbable ties or fine bipolar electrocautery. Measure at least 2.0 to 2.5 cm of mobilized in situ vessel length. Ligate the proximal and distal ends securely with 4-0 silk or vicryl sutures and sharply divide the artery. Submerge the uncrushed specimen immediately in 10% neutral buffered formalin.
• Meticulous Layered Closure: Inspect the bed for hemostasis under low-power bipolar electrocautery. Close the superficial fascia with interrupted 4-0 vicryl sutures; close the skin with running 5-0 nonabsorbable sutures or surgical staples. Apply a light pressure dressing.

Vascular & Endovascular Interventions for Large-Vessel GCA

Surgical and interventional management of large-vessel complications follows strict anatomical and inflammatory criteria:

• Thoracic Aortic Aneurysm Repair: Indicated for ascending thoracic aortic aneurysms measuring 5.5 cm or greater (or expanding > 0.5 cm/year) or descending thoracic aneurysms 6.0 cm or greater. Open surgical graft replacement with Dacron or thoracic endovascular aortic repair (TEVAR) is performed. Acute Stanford Type A aortic dissection requires emergent sternotomy, cardiopulmonary bypass, and ascending aortic graft replacement.
• Upper Extremity Revascularization: Critical upper limb ischemia or symptomatic subclavian steal syndrome refractory to medical therapy is treated with percutaneous transluminal balloon angioplasty with stenting or extra-anatomic bypass (carotid-subclavian bypass). Elective vascular reconstruction must be delayed until systemic vasculitic inflammation has been fully extinguished with immunosuppression to prevent anastomotic thrombosis or prosthetic graft detachment.

Indications & Contraindications

Explicit clinical, surgical, and anatomical thresholds dictate decision-making:

• Indications for Temporal Artery Biopsy: Suspected GCA in patients aged 50 years or older presenting with new headache, elevated ESR/CRP, visual disturbances, jaw claudication, or unexplained constitutional symptoms. (Biopsy remains indicated even if vascular ultrasound is positive in centers following North American practice guidelines).
• Indications for Immediate IV Methylprednisolone Pulse Therapy: Acute visual loss, amaurosis fugax, binocular diplopia, or evolving ischemic stroke in suspected GCA (500 to 1,000 mg IV daily for 3 days).
• Indications for Thoracic Aorta Surgical Intervention: Ascending thoracic aortic aneurysm diameter 55 mm or greater (or 50 mm or greater with rapid growth > 5 mm/year or aortic valve insufficiency); acute Stanford Type A or Type B aortic dissection.
• Indications for Upper Extremity Revascularization: Limb-threatening upper extremity ischemia with rest pain or tissue loss, performed once systemic inflammation is controlled.
• Contraindications to Temporal Artery Biopsy: Active overlying scalp infection, cellulitis, or ulceration; severe, uncorrected coagulopathy (INR > 2.0 or platelets < 50,000/uL).
• Contraindications to Elective Vascular Surgery: Active, unsuppressed systemic vasculitis (ESR > 50 mm/hr, CRP > 20 mg/L) is a relative contraindication to elective vascular reconstruction due to high rates of anastomotic failure and re-stenosis.

9. Outcome

Modern management paradigms have substantially shifted the prognosis of giant cell arteritis, though visual outcomes and glucocorticoid-related morbidity remain major challenges:

• Visual Preservation & Recovery: Established visual loss secondary to arteritic AION or central retinal artery occlusion is permanent; less than 5% to 10% of affected eyes demonstrate meaningful recovery of visual acuity following high-dose glucocorticoid therapy. However, immediate corticosteroid administration is nearly 100% effective in preventing subsequent visual loss in the unaffected contralateral eye.
• Disease Relapse Rates Under Monotherapy vs Biologics: Under conventional glucocorticoid monotherapy, 40% to 50% of patients experience at least one clinical or serological relapse during dose tapering, typically manifesting when prednisone is reduced below 15 to 20 mg daily. The integration of weekly subcutaneous tocilizumab (GiACTA trial) dramatically reduces 1-year relapse rates, achieving 56% sustained glucocorticoid-free remission at 52 weeks versus 14% with placebo. Similarly, selective JAK-1 inhibition with oral upadacitinib (SELECT-GCA trial) produces 46% sustained remission at 52 weeks versus 29% in the active taper comparator.
• Patient-Reported Quality of Life (SF-36): Short Form-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores are reduced by 1.5 to 2 standard deviations below age-matched norms during active disease. Biologic-induced remission produces clinically meaningful improvements exceeding the minimal clinically important difference (MCID > 5 points).
• Functional Disability Index (HAQ-DI): Severe baseline functional disability (mean HAQ-DI 1.2 to 1.6) driven by polymyalgic stiffness and shoulder girdle weakness normalizes within 4 to 8 weeks of systemic anti-inflammatory therapy.
• Vasculitis Damage Accumulation (VDI): Chronic organ damage accumulates over time, with greater than 80% of total Vasculitis Damage Index score points attributable directly to corticosteroid toxicity rather than original vasculitic ischemia.
• Long-Term Survival & Mortality: Overall life expectancy in treated GCA patients without catastrophic aortic rupture or stroke is comparable to the general population. However, patients with large-vessel thoracic aortic aneurysm carry a five-fold increase in cardiovascular mortality if structural surveillance is neglected.

10. Complications

Complications in giant cell arteritis fall into three distinct categories: ischemic disease manifestations, surgical procedural injuries, and iatrogenic immunosuppressive toxicities:

11. Pearls and Pitfalls

• Empiric Glucocorticoid Rescue Pearl: Never delay or withhold systemic corticosteroid administration while awaiting a temporal artery biopsy or vascular ultrasound appointment. Transmural mononuclear infiltrates and internal elastic lamina fragmentation persist on histology for 2 to 4 weeks after initiating high-dose steroids, whereas postponing therapy by even 24 hours risks catastrophic, irreversible bilateral blindness.
• The 2.0 cm In Situ Specimen Rule: Giant cell arteritis is notoriously segmental, with normal arterial architecture alternating with inflamed segments (“skip lesions”). When performing a temporal artery biopsy, always harvest at least 2.0 cm of in situ vessel length (which contracts to 1.5 cm in formalin). Specimens shorter than 1.0 cm carry a false-negative rate exceeding 20%.
• Parietal Branch Anatomical Pearl: To definitively eliminate the risk of injuring the frontal branch of the facial nerve, harvest the parietal (posterior) branch of the superficial temporal artery instead of the frontal branch. The parietal branch provides identical histopathologic diagnostic yield, courses well posterior to the facial nerve danger zone, and hides the surgical scar within the parietal hair-bearing scalp.
• Adventitial Micro-Dissection Pearl: When mobilizing the temporal artery, manipulate the vessel exclusively by its loose periadventitial connective tissue using fine jeweler’s micro-forceps. Never grasp the arterial wall with toothed pickups or apply vascular clamps across the specimen: mechanical crush artifact disrupts the internal elastic lamina, simulating or obscuring true vasculitic elastolysis.
• Ultrasound Compression Sign Pearl: When evaluating the temporal artery with color Doppler ultrasound, distinguish a true vasculitic “halo sign” from acoustic artifact by applying gentle transducer pressure. True inflammatory mural edema produces a hypoechoic halo that remains persistently visible despite total luminal compression (positive compression sign).
• The Normal ESR Trap Pitfall: Do not rule out giant cell arteritis solely because the erythrocyte sedimentation rate is normal. Approximately 1% to 4% of biopsy-proven GCA patients present with an ESR under 30 mm/hr. Always cross-reference with high-sensitivity C-reactive protein (CRP), platelet counts, and clinical presentation.
• The Orthopaedic Shoulder Camouflage Pitfall: In elderly patients presenting to orthopaedic clinics with acute bilateral shoulder pain, profound morning stiffness, and difficulty elevating their arms, resist the temptation to diagnose bilateral rotator cuff tears or adhesive capsulitis without investigating polymyalgia rheumatica. Always query new-onset headaches, scalp tenderness, and jaw claudication before administering subacromial injections or scheduling shoulder arthroscopy.

12. Controversy

Ultrasound-First vs. Biopsy-First Diagnostic Paradigm: EULAR vs. ACR Guidelines

A major international controversy exists regarding the primary diagnostic test for suspected GCA. The updated European League Against Rheumatism (EULAR 2023/2024) recommendations endorse high-resolution color Doppler ultrasound of the temporal and axillary arteries as the preferred first-line diagnostic investigation, asserting that in patients with high clinical pre-test probability, a typical non-compressible hypoechoic “halo sign” performed by an experienced vascular sonographer is sufficient to establish the diagnosis without biopsy. Conversely, North American guidelines (American College of Rheumatology / Vasculitis Foundation 2021) maintain that temporal artery biopsy remains the primary gold standard and should be pursued in all suspected cases, utilizing vascular ultrasound as an adjunct. Proponents of mandatory biopsy emphasize that histology provides definitive tissue confirmation, permanently establishes the diagnosis before committing an elderly patient to years of immunosuppression, and avoids false positives from atherosclerosis or operator variability.

Upfront Biologic Therapy for All vs. Risk-Stratified Glucocorticoid Monotherapy

While the landmark GiACTA (tocilizumab) and SELECT-GCA (upadacitinib) trials conclusively demonstrated superior sustained remission and substantial glucocorticoid-sparing benefits with targeted therapy, debate continues over whether all newly diagnosed patients should receive upfront biologic therapy or if biologics should be restricted to high-risk cohorts. Advocates of universal upfront biologics argue that glucocorticoid-related toxicity affects greater than 80% of patients over two years, resulting in high rates of osteoporotic fractures, diabetes, and infections that can be averted through early steroid withdrawal. Opponents argue that biologic therapy carries substantial financial costs, requires parenteral administration or continuous monitoring, and carries distinct risks such as gastrointestinal perforation (with tocilizumab in patients with diverticulosis) and herpes zoster reactivation (with upadacitinib). Current consensus guidelines recommend a risk-stratified approach, prioritizing upfront biologics for patients with high baseline fracture risk, diabetes, severe osteoporosis, or recurrent relapse.

Accelerated 26-Week vs. Traditional 12-to-18-Month Glucocorticoid Tapering

Historically, glucocorticoid tapering in GCA was conducted over 12 to 24 months to prevent disease rebound. However, recent clinical trials combining glucocorticoids with targeted biologics utilized an accelerated 26-week (6-month) taper, demonstrating high sustained remission rates. Proponents argue that an accelerated 26-week taper dramatically curtails cumulative steroid exposure and minimizes metabolic and skeletal adverse events. Skeptics point out that in both the GiACTA and SELECT-GCA trials, cessation of the biologic agent at 52 weeks was followed by clinical relapse in a significant proportion of patients, suggesting that rapid tapers may suppress systemic acute-phase inflammation without completely extinguishing subclinical vessel-wall vasculitis, leaving patients vulnerable once the targeted agent is stopped.

Clinical Utility of Routine Bilateral Temporal Artery Biopsies

Because giant cell arteritis is a patchy, segmental panarteritis, some surgical centers have historically advocated performing simultaneous or sequential bilateral temporal artery biopsies to maximize diagnostic sensitivity. However, large prospective studies have demonstrated that the discordance rate between bilateral biopsies is only 3% to 5%. In 95% or more of patients, a unilateral biopsy of adequate length (in situ >= 1.5 to 2.0 cm) accurately reflects the pathologic status of the contralateral vessel. Current clinical consensus strongly advises against routine bilateral biopsies, reserving contralateral biopsy for patients whose initial unilateral biopsy is negative or uninterpretable but in whom high clinical suspicion of GCA persists.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Blockmans D, Penn SK, Setty AR et al. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med. 2025. doi:10.1056/NEJMoa2413449 [Level I: Randomized Controlled Trial]
• Maz M, Chung SA, Abril A et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021. doi:10.1002/art.41774 [Level I: Systematic Review / Meta-Analysis]
• Stone JH, Tuckwell K, Dimonaco S et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017. doi:10.1056/NEJMoa1613849 [Level I: Randomized Controlled Trial]
• Buttgereit F, Dejaco C, Matteson EL et al. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA. 2016. doi:10.1001/jama.2016.5444 [Level I: Systematic Review / Meta-Analysis]
• Dejaco C, Ramiro S, Bond M et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024. doi:10.1136/ard-2023-224543 [Level I: Systematic Review / Meta-Analysis]

15. Master Class Pro-Tip

When undertaking a temporal artery biopsy in a patient with suspected giant cell arteritis, surgical success hinges on two non-negotiable principles: anatomical preservation of the frontal branch of the facial nerve and acquisition of an adequate, uncrushed vascular specimen. Always map the superficial temporal artery preoperatively using a continuous-wave Doppler probe or palpation. If choosing the frontal branch over the parietal branch, place your incision well superior to the zygomatic arch and strictly parallel to relaxed skin creases or within the temporal hairline. The fatal anatomical error is plunging deeply into the subgaleal plane: the temporal branch of cranial nerve VII ascends across the zygomatic arch along Pitanguy’s line (from 0.5 cm below the tragus to 1.5 cm superior to the lateral brow) within the sub-temporoparietal fascia. Keep your dissection strictly subcutaneous down to the temporoparietal fascia, where the artery resides. Handle the vessel exclusively by its loose periadventitial tissue using fine jeweler’s forceps; never crush the muscular media with toothed pickups or vascular clamps. Secure at least 2.0 to 2.5 cm of in situ vessel length before divided ligation, which contracts to the requisite 1.5 to 2.0 cm fixed length in formalin, safeguarding against false-negative reports caused by skip lesions. Most critically, never allow surgical scheduling to delay medical rescue: administer systemic corticosteroids immediately upon clinical suspicion, knowing that pathognomonic transmural inflammatory infiltrates and elastolysis remain diagnostic on histology for up to four weeks.

Master Class Surgical Pearl: Temporal Artery Biopsy and Vasculitis Management